Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.94 USD
−54.58 M USD
0.00 USD
68.82 M
About Verona Pharma plc
Sector
CEO
David S. Zaccardelli
Headquarters
London
Website
Founded
2005
FIGI
BBG00GD4KBL1
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.